Kyverna Therapeutics Publishes Primary Analysis Of KYSA-8 Trial In Participants With Stiff Person Syndrome In Journal Of American Medical Association Neurology

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced the publication of the primary analysis of KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS) in the Journal of the American Medical Association (JAMA) Neurology. These published data were presented in a late-breaking oral presentation at the American Academy of Neurology (AAN) Annual Meeting in April 2026. Kyverna also recently shared its one-year durability data from the KYSA-8 trial at MS Toronto, the joint ACTRIMS-ECTRIMS meeting.